Company intelligence / Profile preview

NMT Pharma

Singapore, Singapore

Ownership: Private
Development stage: Other

Overview

NMT Pharma licensed CZ-48, a camptothecin analogue and topoisomerase I inhibitor prodrug, and initiated a Phase I clinical trial in 2016 with first patient recruited. Preclinical data showed low toxicity and efficacy across 22 cancer cell lines.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

CAO Pharmaceuticals Inc.

Beyond the preview

Go deeper on NMT Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NMT Pharma.

Explore the full profile